atorvastatin has been researched along with Genetic Predisposition in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 23 (74.19) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Abdullah, S; Abed, E; Alhawari, H; Jarrar, Y; Zihlif, M | 1 |
| Benaiges, D; Brea-Hernando, Á; Civeira, F; Climent, E; Lafuente, H; Marco-Benedí, V; Ortega-Martínez de Victoria, E; Pedro-Botet, J; Pintó, X; Plana, N; Suárez-Tembra, M; Vila, À | 1 |
| Hellberg, S; Jauhiainen, M; Knuuti, J; Liljenbäck, H; Metso, J; Nuutila, P; Roivainen, A; Saraste, A; Saukko, P; Savisto, N; Silvola, JMU; Sippola, S; Ståhle, M; Virta, J; Ylä-Herttuala, S | 1 |
| Akbari, H; Asadikaram, G; Masoumi, M; Vakili, S | 1 |
| Al-Allaf, FA; Alamanni, F; Aljohani, A; Amin, AA; Bogari, NM; Dannoun, A; Elkhatee, O; Elsayed, A; Fawzy, A; Khogeer, SAA; Porqueddu, M; Rednah, DI; Taher, MM | 1 |
| Chang, HJ; Cho, IJ; Chung, N; Ha, JW; Hong, GR; Hong, SJ; Kang, DR; Park, S; Shim, CY; Shin, S | 1 |
| Gu, GL; Xu, XL; Yang, QY; Zeng, RL | 1 |
| AlBacha, Jd; Azar, A; Fajloun, Z; Haddad, K; Hamoui, S; Khoury, M; Makdissy, N; Mouawad, C | 1 |
| Adámková, V; Češka, R; Dlouhá, D; Hrubá, P; Hubáček, JA; Viklický, O; Vrablík, M; Zlatohlavek, L | 1 |
| Fukunaga, K; Ishikawa, T; Kubo, M; Mushiroda, T; Nakagawa, H | 1 |
| Bai, XD; Dila, NM; Hu, L; Li, YM; Liu, LY; Mao, JP; Yang, XY; Yue, YH; Zhang, HJ | 1 |
| Amudha, K; Choy, AM; Lang, CC; Mustafa, MR | 1 |
| Crosslin, DR; Ginsburg, GS; Messer, C; Reed, CR; Salisbury, BA; Shah, SH; Voora, D; Zhai, J | 1 |
| King, S; Superko, HR | 1 |
| Garg, N; Mittal, B; Srivastava, A; Srivastava, K | 1 |
| Lombardi, R; Marian, AJ; Nagueh, SF; Tan, Y; Wang, J; Willerson, JT | 1 |
| Mombelli, G; Sirtori, CR | 1 |
| Brunham, LR; Carleton, BC; Carter, C; Hayden, MR; Hovingh, GK; Jukema, JW; Kastelein, JJ; Lansberg, PJ; Miao, F; Ross, CJ; Stalenhoef, AF; Visscher, H; Zhang, L | 1 |
| Bonner Freeman, A; Brouwers, MC; Konrad, RJ; Lu, A; Schaper, NC; Stehouwer, CD; Troutt, JS; van Greevenbroek, MM | 1 |
| Nemati, MH | 1 |
| Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C | 1 |
| Gabriel, CL; Kastelein, JJ; Major, AS; Mendez-Fernandez, YV; Stroes, ES; Tak, PP; van Leuven, SI; Wade, NS; Wilhelm, AJ | 1 |
| Guerci, AD; Kastelein, JJ; Mulders, TA; Pinto-Sietsma, SJ; Sivapalaratnam, S; Stroes, ES | 1 |
| Angelica Merlini, P; Antonietta Demola, M; Ardissino, D; Francesca Notarangelo, M; Guidorossi, A; Marziliano, N; Pigazzani, F | 1 |
| Munshi, A | 1 |
| Bacic-Vrca, V; Bozina, N; Horvatic, I; Lisicic, A; Marusic, S | 1 |
| Ahmed, W; Ali, IS; Ali, SH; Azam, M; Niazi, AK; Niazi, SH; Qamar, R; Riaz, M; Sadeque, A; Younas, A | 1 |
| Hirooka, Y; Kishi, T; Mukai, Y; Shimokawa, H; Takeshita, A | 1 |
| Gao, C; Li, WM; Liu, W; Sun, NL | 1 |
| Cuccurullo, F; Di Febbo, C; Di Nisio, M; Guglielmi, MD; Moretta, V; Porreca, E; Stuppia, L | 1 |
| Fidani, L; Giannopoulos, S; Goulas, A; Hatzitolios, AI; Kosmidou, M; Mirtsou, V; Molyva, D | 1 |
5 trial(s) available for atorvastatin and Genetic Predisposition
| Article | Year |
|---|---|
Impact of atorvastatin treatment in first-degree relatives of patients with premature coronary artery disease with endothelial dysfunction: a double-blind, randomized, placebo-controlled crossover trial.
Topics: Age of Onset; Atorvastatin; Biomarkers; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pedigree; Phenotype; Primary Prevention; Prospective Studies; Pyrroles; Republic of Korea; Time Factors; Treatment Outcome | 2013 |
Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Atorvastatin; Blood Flow Velocity; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Pyrroles; Vasodilation; Young Adult | 2008 |
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Topics: Adolescent; Adult; Aged; Alleles; Anticholesteremic Agents; Apolipoprotein E3; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Regression Analysis; Simvastatin | 2008 |
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
Topics: Aged; Analysis of Variance; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Genetic Predisposition to Disease; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Logistic Models; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.
Topics: Age of Onset; Aged; Asymptomatic Diseases; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Pedigree; Primary Prevention; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2012 |
26 other study(ies) available for atorvastatin and Genetic Predisposition
| Article | Year |
|---|---|
The Influence of Endothelial Nitric Oxide Synthase (eNOS) Genetic Polymorphisms on Cholesterol Blood Levels Among Type 2 Diabetic Patients on Atorvastatin Therapy.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Young Adult | 2021 |
Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Phenotype; Registries; Rosuvastatin Calcium; Simvastatin; Spain; Treatment Outcome | 2021 |
Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [
Topics: Animal Feed; Animals; Aortic Diseases; Apolipoprotein B-100; Atherosclerosis; Atorvastatin; Diet, Fat-Restricted; Diet, High-Fat; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Genetic Predisposition to Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Mice, Knockout; Phenotype; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, LDL; Time Factors | 2017 |
Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism.
Topics: Atorvastatin; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genotype; Humans; Hypertension; Losartan; Male; Middle Aged; Monoamine Oxidase; Polymorphism, Single Nucleotide | 2019 |
A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug.
Topics: Adult; Aged; Apolipoprotein A-V; Atorvastatin; Biomarkers; Case-Control Studies; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genetic Variation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Phenotype; Treatment Outcome; Triglycerides; Young Adult | 2019 |
Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease.
Topics: Atorvastatin; China; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Female; Follow-Up Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Pyrroles; Survival Rate | 2014 |
High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cytokines; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lebanon; Male; Middle Aged; Peptidyl-Dipeptidase A; Plasminogen Activator Inhibitor 1; Polymorphism, Single Nucleotide; Ramipril; Treatment Outcome; Young Adult | 2015 |
SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Topics: Aged; Atorvastatin; Czech Republic; Diabetes Mellitus; Dose-Response Relationship, Drug; Dyslipidemias; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Models, Genetic; Muscular Diseases; Myalgia; Obesity; Organic Anion Transporters; Polymorphism, Single Nucleotide; Simvastatin; Smoking | 2015 |
ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.
Topics: Asian People; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cell Line; Chemical and Drug Induced Liver Injury; Genetic Predisposition to Disease; Humans; Japan; Polymorphism, Single Nucleotide | 2016 |
Gene Polymorphisms Affect the Effectiveness of Atorvastatin in Treating Ischemic Stroke Patients.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-V; Atorvastatin; Brain Ischemia; Cholesterol Ester Transfer Proteins; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Hydroxymethylglutaryl CoA Reductases; Lipoprotein Lipase; Lipoproteins, HDL; Lipoproteins, LDL; Middle Aged; Polymorphism, Single Nucleotide; Proprotein Convertase 9; Stroke | 2016 |
Letter by Superko and King regarding article, "Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals".
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Genetic Predisposition to Disease; Goals; Guideline Adherence; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinesins; Male; Middle Aged; Mutation, Missense; Patient Selection; Pravastatin; Pyrroles; Risk | 2010 |
Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Case-Control Studies; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genotype; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiomegaly; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Male; Middle Aged; Pilot Projects; Pyrroles; Statistics as Topic; Treatment Outcome; Young Adult | 2010 |
Cholesteryl ester transfer protein antagonism by drugs--a poor choice.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Polymorphism, Genetic; Pyrroles; Quinolines; Risk | 2010 |
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Topics: Adult; Aged; Atorvastatin; British Columbia; Case-Control Studies; Chi-Square Distribution; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Netherlands; Odds Ratio; Organic Anion Transporters; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Risk Assessment; Risk Factors; Severity of Illness Index; Simvastatin | 2012 |
Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.
Topics: Adult; Aged; Apolipoproteins B; Atorvastatin; Body Mass Index; Family Health; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Insulin Resistance; Lipoproteins, VLDL; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Sterol Regulatory Element Binding Protein 2 | 2011 |
Bilateral carotid atherosclerosis: an inevitable consequence of homozygous familial hypercholesterolemia.
Topics: Angioplasty; Atorvastatin; Carotid Stenosis; Disease Progression; Genetic Predisposition to Disease; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver Transplantation; Phenotype; Pyrroles; Radiography; Severity of Illness Index; Stents; Time Factors; Treatment Outcome; Treatment Refusal | 2011 |
Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.
Topics: Animals; Atherosclerosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mycophenolic Acid; Pyrroles | 2012 |
Genetic predisposition to atorvastatin-induced myopathy: a case report.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Genetic; Pyrroles | 2012 |
Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Female; Follow-Up Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Ischemia; Lipoprotein Lipase; Male; Middle Aged; Minisatellite Repeats; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Prognosis; Pyrroles; Risk Factors; Stroke | 2012 |
Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Kidney Injury; Aged; Aryl Hydrocarbon Hydroxylases; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pantoprazole; Polymorphism, Single Nucleotide; Proton Pump Inhibitors; Pyrroles; Renal Dialysis; Rhabdomyolysis; Risk Factors; Treatment Outcome | 2012 |
Association of ANRIL polymorphism (rs1333049:C>G) with myocardial infarction and its pharmacogenomic role in hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Drug Resistance; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pakistan; Polymorphism, Single Nucleotide; Pyrroles; Risk; RNA, Long Noncoding; Sequence Analysis, DNA; Triglycerides | 2013 |
Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; Brain; Genetic Predisposition to Disease; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Isoenzymes; Lipids; Male; Myocardium; Neural Inhibition; Nitric Oxide Synthase; Norepinephrine; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Sympathetic Nervous System; Up-Regulation | 2003 |
Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats.
Topics: Animals; Atorvastatin; Autoimmune Diseases; Cholesterol; Cytokines; Genetic Predisposition to Disease; Heart Function Tests; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocarditis; Myocardium; Pyrroles; Rats; Rats, Inbred Lew; Th1 Cells; Th2 Cells | 2005 |
Effects of toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; P-Selectin; Phenotype; Polymorphism, Genetic; Pyrroles; Risk Factors; Toll-Like Receptor 4; Treatment Outcome; von Willebrand Factor | 2007 |
Glutathione S-transferase null and cholesteryl ester transfer protein TaqI B polymorphisms and lipid response to atorvastatin in Greek dyslipidaemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Female; Gene Silencing; Genetic Predisposition to Disease; Genotype; Glutathione Transferase; Greece; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Reference Values | 2008 |